Revance Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Revance Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
  • Revance Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$32.3M, a 14.1% increase year-over-year.
  • Revance Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$290M, a 1.66% decline year-over-year.
  • Revance Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$317M, a 7.36% increase from 2022.
  • Revance Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$342M, a 24.5% decline from 2021.
  • Revance Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$275M, a 0.55% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$317M +$25.2M +7.36% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$342M -$67.3M -24.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$275M -$1.51M -0.55% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$273M -$109M -66.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$164M -$21.8M -15.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$143M -$22.2M -18.4% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$120M -$32.2M -36.5% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 -$88.2M -$15.9M -22% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$72.3M -$20.3M -38.9% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-02
2014 -$52.1M -$13.8M -36.2% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-28
2013 -$38.2M -$6.46M -20.3% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-04
2012 -$31.8M Jan 1, 2012 Dec 31, 2012 10-Q 2015-08-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.